We studied a set of potential biomarkers (Eotaxin-3, TARC/CCL17, IgG4, and IgG4/IgG ratio) for disease relapse in a prospective, well-defined EGPA cohort. This evidence concerns the gene CCL26 and eosinophilic granulomatosis with polyangiitis.